Warning letter
Hybrid Pharma, LLC: warning letter of Jun 7, 2022
FDA warning letter 629021 · Office of Pharmaceutical Quality Operations, Division II
Key facts
| Reference number | 629021 |
|---|---|
| Company | Hybrid Pharma, LLC |
| Subject | Compounding Pharmacy/Adulterated Drug Products |
| Issue date | Jun 7, 2022 |
| Posted date | Jun 14, 2022 |
| Issuing office | Office of Pharmaceutical Quality Operations, Division II |
| Product type | Drugs |
| CFR sections cited | 211.42(c)(10)(iv), 201.115, 210.1(b), 200.10(b), 211.192, 211.165(e) |
| Inspection city | Deerfield Beach |
| Inspection ZIP | 33442 |
| Inspection start date | Jul 27, 2021 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: